High-Grade, Low Prostate-Specific Antigen Prostate Cancer: Unique Hormone-Resistant Entity with Poor Survival

Vikash Kumar

doi:10.4103/ijmpo.ijmpo_55_20

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 481-483
DOI: 10.4103/ijmpo.ijmpo_55_20

Editorial Commentary

High-Grade, Low Prostate-Specific Antigen Prostate Cancer: Unique Hormone-Resistant Entity with Poor Survival

Vikash Kumar

Department of Radiation Oncology, Asian Institute of Medical Sciences, Faridabad, Haryana, India

References
1 Kim J, Coetzee GA. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 2004; 93: 233-41
2 Aggarwal R, Zhang T, Small EJ, Armstrong AJ. Neuroendocrine prostate cancer: Subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw 2014; 12: 719-26
3 Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004; 45: 586-92
4 Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE. et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 2014; 38: 756-67
5 Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY. et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1: 487-95
6 Deorah S, Rao MB, Raman R, Gaitonde K, Donovan JF. Survival of patients with small cell carcinoma of the prostate during 1973-2003: A population-based study. BJU Int 2012; 109: 824-30
7 Mahal BA, Aizer AA, Efstathiou JA, Nguyen PL. Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. Cancer 2016; 122: 78-83
8 Alshalalfa M, Santiago Jimenez M, Erho N, Fishbane N, Yousefi K, Al-Deen AH. et al. Relationships between an androgen receptor output signature (ARoS), AR expression, and poor prostate cancer prognosis in RP tissues. J Clin Oncol 2017; 6 Suppl 35: 38
9 Alshalalfa M, Tsai H, Haddad Z, Ross A, Karnes RJ, Davicioni E. Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility. J Clin Oncol 2016; 2: 303 et al. Suppl 34
10 Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The national cancer data base: A powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008; 15: 683-90
11 National Cancer Institute. Overview of the SEER Program. https://seer.cancer.gov/about/overview.html Available from: [Last accessed on 2020 Jul 17]
12 National Cancer Institute. PSA values and SEER data. https://seer.cancer.gov/data/psa-values.html Available from: [Last accessed on 2020 Jul 17]
13 Sella A, Konichezky M, Flex D, Sulkes A, Baniel J. Low PSA metastatic androgen-independent prostate cancer. Eur Urol 2000; 38: 250-4
14 Nishio R, Furuya Y, Nagakawa O, Fuse H. Metastatic prostate cancer with normal level of serum prostate-specific antigen. Int Urol Nephrol 2003; 35: 189-92
15 Sandler HM, Hu C, Rosenthal SA, Sartor O, Gomell LG. et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). J Clin Oncol 2015; 18 Suppl 33: LBA5002
16 James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387: 1163-77